Australia's most trusted
source of pharma news
Thursday, 16 April 2026
Posted 15 April 2026 PM
Kazia Therapeutics is positioning itself to become a player in the epigenetic therapy market, acquiring global rights to QIMR Berghofer’s SETDB1 platform, including lead candidate MSETC.
Financial terms include a $1.39 million upfront payment and a tiered revenue-sharing structure aligned with development progress, with no clinical or regulatory milestone obligations.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.